Eli Lilly has released Phase 3 trial results for orforglipron, an oral GLP-1 drug that produces weight loss comparable to injectable Ozempic, potentially transforming the obesity treatment landscape.

Trial Results

Patients taking the daily pill lost an average of 14.7% body weight over 36 weeks, compared to 15.2% for semaglutide injections. The difference was not statistically significant.

Game Changer

An effective pill form eliminates the need for weekly injections, addresses supply shortages, and could dramatically reduce costs. Analysts project the oral GLP-1 market could reach $50 billion by 2030.